Welcome to our dedicated page for CLRBW news (Ticker: CLRBW), a resource for investors and traders seeking the latest updates and insights on CLRBW stock.
Cellectar Biosciences, Inc. (CLRBW) is a clinical-stage biopharmaceutical company pioneering targeted cancer treatments through its proprietary Phospholipid Drug Conjugate™ (PDC™) platform. This page provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access consolidated, verified information about Cellectar’s radiopharmaceutical pipeline including iopofosine I-131 for hematologic cancers and actinium-based therapies for solid tumors. Our news collection covers essential updates including trial results, FDA designations, manufacturing collaborations, and financial disclosures.
Key content areas include progress reports on late-stage clinical programs, analyses of therapeutic mechanisms, and coverage of scientific presentations. All materials maintain strict compliance with financial disclosure regulations while prioritizing accessibility for both specialist and general audiences.
Bookmark this page for streamlined tracking of Cellectar’s advancements in precision oncology. For comprehensive monitoring of CLRBW developments, consider subscribing to our news alerts or consulting additional regulatory filings.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has scheduled its first quarter 2025 financial results announcement and corporate update for May 13, 2025, at 8:30 AM ET. The company will host a conference call accessible via toll-free number 1-800-717-1738 (Conference ID: 53983) and webcast. A replay of the presentation will be made available in the Events section of the company's Investor Relations website.
Cellectar Biosciences (NASDAQ: CLRB) has announced plans to explore strategic alternatives to maximize stockholder value. The company, which focuses on cancer drug development, is considering various options including mergers, acquisitions, partnerships, joint ventures, and licensing arrangements.
The company has engaged Oppenheimer & Co as exclusive financial advisor for the strategic evaluation process. CEO James Caruso highlighted their key asset iopofosine I 131, along with alpha- and Auger-emitting radioconjugates (CLR 225 and CLR 125) for solid tumor treatments.
While no specific timetable has been set for the evaluation process, Cellectar emphasizes that no agreements have been reached, and there are no guarantees that the process will result in any transaction. The company will only disclose further information when deemed necessary.
Cellectar Biosciences (NASDAQ: CLRB) reported financial results for 2024 and provided corporate updates. The company achieved FDA alignment for potential accelerated approval of iopofosine I 131 for Waldenström macroglobulinemia (WM) treatment. The Phase 2 CLOVER-WaM study showed an 83.6% Overall Response Rate and 58.2% Major Response Rate.
Financial highlights include cash and equivalents of $23.3 million as of December 31, 2024, compared to $9.6 million in 2023. The company raised $44.1 million through warrant exercises in January 2024 and $19.4 million in July 2024. R&D expenses decreased to $26.1 million from $27.3 million, while G&A expenses increased to $25.6 million from $11.7 million. Net loss was $44.6 million ($1.22 per basic share).
The company plans Phase 1 solid tumor studies with two radioconjugate compounds: CLR 121125 for triple-negative breast cancer and CLR 121225 for pancreatic cancer, with an IND submission planned for first half 2025.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has announced its participation in the 37th Annual Roth Conference. The company's management team will deliver a corporate presentation on Monday, March 17, 2025, at 8:30 AM Eastern Time.
The presentation will provide an overview of the company and its operations. Interested parties can access the presentation through a webcast link, and a replay will be made available in the Events section of Cellectar's Investor Relations website.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has scheduled its full year 2024 financial results announcement and corporate update for March 13, 2025, at 8:30 a.m. Eastern Time. The company will make a replay of the conference call available through their Investor Relations website's Events section.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management team will deliver a corporate presentation on Wednesday, February 12, 2025, at 12:00 PM Eastern Time.
The conference will be held virtually, and interested parties can access the presentation through a provided webcast link. Following the live presentation, a replay will be made available in the Events section of Cellectar's investor relations website.
Cellectar Biosciences (NASDAQ: CLRB) announced its 2025 strategic initiatives, highlighting significant progress with its cancer treatment drug Iopofosine I 131. The company reported impressive Phase 2 CLOVER-WaM study results, achieving an 83.6% overall response rate and exceeding primary endpoints in treating Waldenstrom's Macroglobulinemia.
The company is finalizing its confirmatory study for FDA accelerated approval and EMA authorization, expecting to enroll 40-60 patients per arm with completion projected within 18 months. Cellectar's cash runway extends into Q4 2025, and they're exploring various approaches to commercialize Iopofosine.
Additionally, Cellectar is advancing two other radiotherapeutic assets: CLR 121225, an alpha-emitting radioconjugate showing promising results in solid tumor models, with IND filing planned for Q1 2025, and CLR 121125, an Auger-emitting PRC with IND clearance for triple-negative breast cancer trials.
